During the Microbiome Connect Europe conference, held early in July in Amsterdam, Microbiomepost discussed with Osnat Tirosh, Head of Microbiome Research & Innovation at Biomica, about the latest updates from the PRISM platform towards obtaining high-resolution profiling of microbial communities both at the taxonomic and the functional levels and the validation of the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models.
Home > Gastroenterology > Validating the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models
Validating the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models
Staff editor
09.08.2023
Osnat Tirosh, Head of Microbiome Research & Innovation at Biomica, talks about the validation of the mechanism of action of BMC333 consortia through pre-clinical studies in IBD models.
Latest related content
Endocrinology, Nutrition
Healthcare professionals area, Neuroscience
Healthcare professionals area
Oncology, Gastroenterology
Latest News
Endocrinology, Nutrition
Healthcare professionals area, Neuroscience
Healthcare professionals area
Oncology, Gastroenterology